This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Entenza, J. M.
Right arrow Articles by Moreillon, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Entenza, J. M.
Right arrow Articles by Moreillon, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 171-177, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.171-177.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

BAL9141, a Novel Extended-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococcus aureus in Treatment of Experimental Endocarditis

J. M. Entenza,1 P. Hohl,2 I. Heinze-Krauss,3 M. P. Glauser,1 and P. Moreillon1*

CHUV, Lausanne,1 F. Hoffmann-La Roche AG,2 Basilea Pharmaceutica, Basel, Switzerland3

Received 30 March 2001/ Returned for modification 20 August 2001/ Accepted 5 October 2001

The therapeutic efficacy of BAL9141 (formerly Ro 63-9141), a novel cephalosporin with broad in vitro activity that also has activity against methicillin-resistant Staphylococcus aureus (MRSA), was investigated in rats with experimental endocarditis. The test organisms were homogeneously methicillin-resistant S. aureus strain COL transformed with the penicillinase-encoding plasmid pI524 (COL Bla+) and homogeneously methicillin-resistant, penicillinase-producing isolate P8-Hom, selected by serial exposure of parent strain P8 to methicillin. The MICs of BAL9141 for these organisms (2 mg/liter) were low, and BAL9141was bactericidal in time-kill curve studies after 24 h of exposure to either two, four, or eight times the MIC. Rats with experimental endocarditis were treated in a three-arm study with a continuous infusion of BAL5788 (formerly Ro 65-5788), a carbamate prodrug of BAL9141, or with amoxicillin-clavulanate or vancomycin. The rats were administered BAL9141 to obtain steady-state target levels of 20, 10, and 5 mg of per liter or were administered either 1.2 g of amoxicillin-clavulanate (ratio 5:1) every 6 h or 1 g of vancomycin every 12 h at changing flow rates to simulate the pharmacokinetics produced in humans by intermittent intravenous treatment. Treatment was started 12 h after bacterial challenge and lasted for 3 days. BAL9141 was successful in the treatment of experimental endocarditis due to either MRSA isolate COL Bla+ or MRSA isolate P8-Hom at the three targeted steady-state concentrations and sterilized >90% of cardiac vegetations (P < 0.005 versus controls; P < 0.05 versus amoxicillin-clavulanate and vancomycin treatment groups). These promising in vivo results with BAL9141 correlated with the high affinity of the drug for PBP 2a and its stability to penicillinase hydrolysis observed in vitro.

* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. Phone: 41-21-3141026. Fax: 41-21-3141036. E-mail: pmoreill{at}chuv.hospvd.ch.

Antimicrobial Agents and Chemotherapy, January 2002, p. 171-177, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.171-177.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kimko, H., Xu, X., Nandy, P., Samtani, M. N., Strauss, R. S., Bagchi, P., Noel, G. J. (2009). Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 3371-3374 [Abstract] [Full Text]  
  • Livermore, D. M. (2008). Future directions with daptomycin. J Antimicrob Chemother 62: iii41-iii49 [Abstract] [Full Text]  
  • Craig, W. A., Andes, D. R. (2008). In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models. Antimicrob. Agents Chemother. 52: 3492-3496 [Abstract] [Full Text]  
  • Chung, M., Antignac, A., Kim, C., Tomasz, A. (2008). Comparative Study of the Susceptibilities of Major Epidemic Clones of Methicillin-Resistant Staphylococcus aureus to Oxacillin and to the New Broad-Spectrum Cephalosporin Ceftobiprole. Antimicrob. Agents Chemother. 52: 2709-2717 [Abstract] [Full Text]  
  • Pillar, C. M., Aranza, M. K., Shah, D., Sahm, D. F. (2008). In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 61: 595-602 [Abstract] [Full Text]  
  • Noel, G. J., Strauss, R. S., Amsler, K., Heep, M., Pypstra, R., Solomkin, J. S. (2008). Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 37-44 [Abstract] [Full Text]  
  • Arias, C. A., Singh, K. V., Panesso, D., Murray, B. E. (2007). Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 60: 594-598 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Pypstra, R., Kahn, J. B., Murthy, B. P., Kimko, H. C., Bush, K., Noel, G. J., Drusano, G. L. (2007). Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrob. Agents Chemother. 51: 2378-2387 [Abstract] [Full Text]  
  • Davies, T. A., Page, M. G. P., Shang, W., Andrew, T., Kania, M., Bush, K. (2007). Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 2621-2624 [Abstract] [Full Text]  
  • Arias, C. A., Singh, K. V., Panesso, D., Murray, B. E. (2007). Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including {beta}-Lactamase-Producing and Vancomycin-Resistant Isolates. Antimicrob. Agents Chemother. 51: 2043-2047 [Abstract] [Full Text]  
  • Bogdanovich, T., Ednie, L. M., Shapiro, S., Appelbaum, P. C. (2005). Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 4210-4219 [Abstract] [Full Text]  
  • Vaudaux, P., Gjinovci, A., Bento, M., Li, D., Schrenzel, J., Lew, D. P. (2005). Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3789-3793 [Abstract] [Full Text]  
  • Chambers, H. F. (2005). Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 884-888 [Abstract] [Full Text]  
  • Vouillamoz, J., Entenza, J. M., Hohl, P., Moreillon, P. (2004). LB11058, a New Cephalosporin with High Penicillin-Binding Protein 2a Affinity and Activity in Experimental Endocarditis Due to Homogeneously Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48: 4322-4327 [Abstract] [Full Text]  
  • Fuda, C., Suvorov, M., Vakulenko, S. B., Mobashery, S. (2004). The Basis for Resistance to {beta}-Lactam Antibiotics by Penicillin-binding Protein 2a of Methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 279: 40802-40806 [Abstract] [Full Text]  
  • Schmitt-Hoffmann, A., Roos, B., Schleimer, M., Sauer, J., Man, A., Nashed, N., Brown, T., Perez, A., Weidekamm, E., Kovacs, P. (2004). Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers. Antimicrob. Agents Chemother. 48: 2570-2575 [Abstract] [Full Text]  
  • Schmitt-Hoffmann, A., Nyman, L., Roos, B., Schleimer, M., Sauer, J., Nashed, N., Brown, T., Man, A., Weidekamm, E. (2004). Multiple-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers. Antimicrob. Agents Chemother. 48: 2576-2580 [Abstract] [Full Text]  
  • Huang, V., Brown, W. J., Rybak, M. J. (2004). In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci. Antimicrob. Agents Chemother. 48: 2719-2723 [Abstract] [Full Text]  
  • Anderegg, T. R., Jones, R. N., Sader, H. S. (2004). Quality Control Guidelines for BAL9141 (Ro 63-9141), an Investigational Cephalosporin, When Reference MIC and Standardized Disk Diffusion Susceptibility Test Methods Are Used. J. Clin. Microbiol. 42: 3356-3358 [Abstract] [Full Text]  
  • Mouton, J. W., Schmitt-Hoffmann, A., Shapiro, S., Nashed, N., Punt, N. C. (2004). Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141. Antimicrob. Agents Chemother. 48: 1713-1718 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Schmitt-Hoffmann, A., Schleimer, M., Shapiro, S. (2004). Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 48: 1105-1111 [Abstract] [Full Text]  
  • Katayama, Y., Zhang, H.-Z., Chambers, H. F. (2004). PBP 2a Mutations Producing Very-High-Level Resistance to Beta-Lactams. Antimicrob. Agents Chemother. 48: 453-459 [Abstract] [Full Text]  
  • Bozdogan, B., Esel, D., Whitener, C., Browne, F. A., Appelbaum, P. C. (2003). Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 52: 864-868 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»